Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

CAR T-cell therapy for refractory/relapsed primary breast lymphoma: A retrospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

XMXi MingXZXiaojian Zhu

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis shows CAR T-cell therapy achieves 63.6% complete response in relapsed breast lymphoma, indicating promising safety profile.

Key Points

  • To analyze the effectiveness and safety of CAR T-cell therapy in patients with relapsed primary breast lymphoma.
  • Retrospective cohort study of 11 patients with relapsed primary breast lymphoma.
  • Evaluated CD19 CAR T and dual CD19/CD22 CAR T-cell therapies, with or without ASCT.
  • Assessed clinical outcomes and adverse effects post-treatment.
  • Eight out of eleven patients achieved complete response (72.73%).
  • Overall survival rate at 1 year was 63.6%.
  • No patients experienced severe cytokine release syndrome or neurotoxicity.

Cite This Study

Ming et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8f7https://doi.org/10.1182/blood-2025-7245
View Full Paper
Ask AI
Bookmark
Share